glp-1 agonist indications The expanding benefits of medicines: Cell Reports Medicine Current Insights, Advantages and Challenges
Description
10.1007/s13300-024-01566-x
The consistent results from sensitivity analyses using the Cox proportional hazards model with alternative sets of covariates and various exclusion criteria confirmed the robustness of our findings (Supplemental Table 8)
Use of GLP-1 Ras, in people with obesity (PwO) may also have skeletal impacts in part because obesity may itself predispose to altered micro-architecture and greater fracture risk
Lingvay, P
The first report of angioedema and anaphylaxis with temporal association to semaglutide
Perret-Guillaume C, Joly L, Benetos A
